Physician profile
John P Day
NPI 1649213182
$8,629.78
in general payments reported to CMS, 2019-2025
41 companies · $595 in 2025
The $595 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $733 · 2021: $1,359 · 2022: $1,398 · 2023: $1,714 · 2024: $1,625 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842 · Education: $92.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,841.59 |
| Education | $92.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,246.17 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,603.54 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $1,367.02 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,015.01 | 2019-2024 | Entyvio |
| Pfizer INC. | $400.98 | 2022-2025 | |
| Genzyme Corporation | $170.32 | 2022-2025 | |
| Celgene Corporation | $154.50 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $137.89 | 2021-2025 | Gimoti |
| Qol Medical, LLC | $120.79 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $119.84 | 2020-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $112.73 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $105.39 | 2019-2024 | Sutab, Suflave |
| Gilead Sciences, INC. | $88.62 | 2019-2024 | |
| Redhill Biopharma INC. | $84.70 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $81.87 | 2019-2023 | Rebyota |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.